Cell Biology, Cell Signaling and Neuroscience, Kinase/Phosphatase Biology, New Products, Protein Kinases (PK), Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors
{SNA} Cell Biology, Cell Signaling and Neuroscience, Kinase/Phosphatase Biology, Protein Kinases (PK), Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors
产品应用
AZD-1152 HQPA, also known as AZD-2811, is a potent and selective Aurora B inhibitor (IC50 of 0.37 nM versus 1368 nM for Aurora B and A kinases, respectively) and is also an active metabolite of Barasertib ( AZD-1152). Barasertib is a prodrug and will be converted rapidly to the active drug AZD1152-HQPA in human plasma. Preliminary studies showed that AZD-1152 was active against a variety of solid tumors including colon, breast, and lung cancers. IMPORTANT NOTE: AZD-1152HQPA IS NOT AZD-1152 or Barasertib. Many vendors is selling Barasertib with wrong structure
相关文献及参考
Mori, N., et al., Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochem. Pharmacol. 81 , 1106-1115, (2011)
Lordier, L., et al., Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood 116 , 2345-2355, (2010)
Grundy, M., et al., The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol. Cancer Ther. 9 , 661-672, (2010)
安全信息
WGK Germany
3
Storage condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).